Do cathepsins play a role in abdominal aortic aneurysm pathogenesis?
Between 1998 and 1999 we suggested a role for cysteine proteases, particularly cathepsins S and K, in atherosclerosis and abdominal aortic aneurysm (AAA) formation. We also demonstrated the presence and activity of cathepsins S, K, and L in atherosclerotic and aneurysmal lesions in humans. Features unique to this family of extracellular enzymes indicate its likely participation in these vascular diseases. As very potent elastolytic enzymes, cathepsins are strong candidates as key participants in aneurysm development. Importantly, cathepsins express very high elastolytic activity in AAA due to reciprocal correlation with cystatin C, their most abundant endogenous inhibitor. Two opposite processes coexist in aneurysmal tissue: overexpression of elastolytic cathepsins, and severe suppression of cystatin C, probably due to differentially regulated expression and secretion of cathepsins and their inhibitors in response to inflammatory cytokines. Involvement of cathepsins in microvessel formation, a pathophysiological marker of human AAA, and programmed cell death (apoptosis), increases the likelihood of cathepsin participation in AAA formation and growth. We also summarize here results obtained in our and other laboratories that demonstrated reduced atherosclerosis and AAA in in vivo models using mice lacking different cathepsins. Deficiency of cysteine protease inhibitor cystatin C in atherosclerosis-prone ApoE-null mice leads to the development of specific features of AAA such as thinning of the tunica media and aortic dilatation. Taken together, such findings in humans in vitro with different cell types and in vivo in genetically altered mice demonstrate the importance of cysteine protease/protease inhibitor balance in dysregulated arterial integrity and remodeling during atherosclerosis and aortic aneurysm formation.
Sukhova
Galina K
GK
Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB-7, Room 730J, Boston, MA 02115, USA. gsukhova@rics.bwh.harvard.edu
Shi
Guo-Ping
GP
D000818:Animals; D017544:Aortic Aneurysm, Abdominal / Q000201:enzymology* / Q000209:etiology* / Q000473:pathology; D017209:Apoptosis; D050197:Atherosclerosis / Q000201:enzymology / Q000473:pathology; D002403:Cathepsins / Q000378:metabolism*; D003094:Collagen / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000378:metabolism; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000201:enzymology; D011480:Protease Inhibitors / Q000494:pharmacology
D011480:Protease Inhibitors; D003094:Collagen; D002403:Cathepsins; D003546:Cysteine Endopeptidases